» Articles » PMID: 35669967

Prospective Quantitative Gene Expression Analysis of Kallikrein-related Peptidase As a Diagnostic Biomarker for Childhood Acute Lymphoblastic Leukemia

Overview
Journal PeerJ
Date 2022 Jun 7
PMID 35669967
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The most common malignancy in children is acute lymphoblastic leukemia (ALL). This study aimed to explore mRNA expression as a potential diagnostic biomarker for ALL in children and to examine the effect of chemotherapy on mRNA expression following the induction and after three months of receiving chemotherapy.

Methods: In this prospective study, total RNA was extracted from blood samples of 23 pediatric ALL patients on diagnosis, after one month and three months of receiving chemotherapy. Healthy pediatric volunteers ( = 12) were selected as control individuals. After cDNA synthesis, mRNA gene expression levels were quantified using quantitative real-time PCR (qRT-PCR).

Results: mRNA expression levels were significantly decreased in leukemic cells compared to their levels in cells of normal blood samples ( = 0.0001). expression levels in ALL patients after one month and three months of receiving chemotherapy decreased compared to normal blood samples ( < 0.0001 and = 0.0175 respectively). The expression level of mRNA in ALL patients after one month of chemotherapy was decreased compared to their level on diagnosis ( = 0.4413). mRNA expression levels in ALL patients after three months of chemotherapy were increased compared to their level on diagnosis ( = 0.0602). The ROC curve illustrated that mRNA expression could very efficiently discriminate ALL patients from normal counterparts (AUC=0.886, 95% CI [0.7720-1.000], SE = 0.0582, = 0.0004).

Conclusion: mRNA expression could serve as a potential diagnostic molecular biomarker for ALL in children.

References
1.
Smith L, Glaser A, Kinsey S, Greenwood D, Chilton L, Moorman A . Long-term survival after childhood acute lymphoblastic leukaemia: population-based trends in cure and relapse by clinical characteristics. Br J Haematol. 2018; 182(6):851-858. DOI: 10.1111/bjh.15424. View

2.
Jost F, Zierk J, Le T, Raupach T, Rauh M, Suttorp M . Model-Based Simulation of Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia. Front Physiol. 2020; 11:217. PMC: 7093595. DOI: 10.3389/fphys.2020.00217. View

3.
Bassan R, Hoelzer D . Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011; 29(5):532-43. DOI: 10.1200/JCO.2010.30.1382. View

4.
Pampalakis G, Diamandis E, Sotiropoulou G . The epigenetic basis for the aberrant expression of kallikreins in human cancers. Biol Chem. 2006; 387(6):795-9. DOI: 10.1515/BC.2006.100. View

5.
Stefanini A, da Cunha B, Henrique T, Tajara E . Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes. Dis Markers. 2016; 2015:946572. PMC: 4689925. DOI: 10.1155/2015/946572. View